In vitro and in vivo NB models studies have indicated the potential usefulness of ALK inhibitors in the presence of an activating ALK mutation 9–11 and a phase 1/2 study of crizotinib, a dual ALK/MET inhibitor, supports further investigation of efficacy in the subset of NB harboring ALK mutations 12. This evidence concerns the gene ALK and neuroblastoma.